The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study.
Gregory C McDermottXiaoqing FuClaire CookCatherine AholaBrett DolinerJennifer HanbergJohn H StoneHyon K ChoiYuqing ZhangZachary Scott WallacePublished in: Annals of the rheumatic diseases (2022)
In this emulated target trial from a large AAV cohort, achieving serological remission within 180 days of induction was associated with lower risk of relapse, but no statistically significant difference in ESRD or mortality outcomes.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- phase iii
- study protocol
- cardiovascular events
- clinical trial
- phase ii
- disease activity
- free survival
- risk factors
- ulcerative colitis
- coronary artery disease
- randomized controlled trial
- cardiovascular disease
- type diabetes
- systemic lupus erythematosus
- metabolic syndrome
- insulin resistance
- skeletal muscle
- weight loss
- placebo controlled
- double blind